



Claris Lifesciences Limited  
 Regd. Office: Claris Corporate Headquarters, Nr. Parimal Railway Crossing, Ellisbridge, Ahmedabad – 380006  
 website : www.clarislifesciences.com, e-mail : investorservices.corp@clarislifesciences.com

Unaudited Financial Results for the Quarter ended March 31, 2013

(Rs. In Lacs except EPS and Shares)

Particulars	Standalone				Consolidated			
	Quarter Ended		Year ended		Quarter Ended		Year ended	
	31st March 2013	31st December 2012	31st March 2012	31st December 2012	31st March 2013	31st December 2012	31st March 2012	31st December 2012
	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Audited
<b>PART II</b>								
<b>A PARTICULARS OF SHAREHOLDING</b>								
<b>1. Public Shareholding</b>								
- No. of shares	24,212,434	24,212,434	19,783,459	24,212,434	24,212,434	24,212,434	19,783,459	24,212,434
- Percentage of shareholding	37.94%	37.94%	31.00%	37.94%	37.94%	37.94%	31.00%	37.94%
<b>2. Promoters and Promoter group shareholding</b>								
<b>a) Pledged/Encumbered</b>								
- Number of shares	7,724,000	7,724,000	9,154,930	7,724,000	7,724,000	7,724,000	9,154,930	7,724,000
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	19.50%	19.50%	20.79%	19.50%	19.50%	19.50%	20.79%	19.50%
- Percentage of shares (as a% of the total share capital of the Company)	12.10%	12.10%	14.35%	12.10%	12.10%	12.10%	14.35%	12.10%
<b>b) Non-encumbered</b>								
- Number of Shares	31,881,331	31,881,331	34,879,376	31,881,331	31,881,331	31,881,331	34,879,376	31,881,331
- Percentage of shares (as a% of the total shareholding of promoter and promoter group)	80.50%	80.50%	79.21%	80.50%	80.50%	80.50%	79.21%	80.50%
- Percentage of shares (as a % of the total share capital of the Company)	49.96%	49.96%	54.65%	49.96%	49.96%	49.96%	54.65%	49.96%
<b>B INVESTOR COMPLAINTS</b>								
Pending at the beginning of the quarter					-			
Received during the quarter					-			
Disposed of during the quarter					-			
Remaining unresolved at the end of the quarter					-			

**Notes:**

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 10th May, 2013.
- 2 The Company has only one reportable business segment, namely, Drugs & Pharmaceuticals.
- 3 On December 7, 2012, the management of the Company entered in to certain agreements with Otsuka Pharmaceutical Factory, Inc., Japan Otsuka and Mitsui & Co. Ltd., Japan (Mitsui) for transfer of its Infusion Business to Claris Otsuka Limited, a wholly owned subsidiary of the Company on slump sale basis. The Company has received the shareholder's approval and it is working towards to attaining the other regulatory approvals and customary closing formalities. The Company operates under a single business segment, and in view of common employees, marketing expenses, logistics and distribution arrangements and general corporate overheads, which are not separately identifiable for identified products of the infusion business being transferred, the Company is unable to determine the income and expenses clearly attributable to the discontinuing operation. Under the facts and circumstances, the Company is unable to disclose separately the profit from the continuing and discontinuing operations, tax expense of discontinuing operations and profit from discontinuing operations after tax.

Necessary disclosures pertaining to the discontinuing operations and reorganisation of the business are as under: -

Rs in Lacs

Particulars	----- Quarter ended -----		Year ended	
	31st March 2013	31st December 2012	31st March 2012	31 <sup>st</sup> December, 2012
Revenue	8,235.00	12,383.00	8,218.00	42,854.56

- 4 The figures for the previous year / period have been regrouped / rearranged wherever necessary.

**For Claris Lifesciences Ltd**

**Place : Mumbai**  
**Date : 10th May, 2013**

Arjun S. Handa  
**Managing Director & CEO**